Brazil Point of Care Diagnostics Market (2024-2029)
The Brazil Point of Care Diagnostics Market was valued at $158.8 Million in 2024 and projected to reach to $231.4 Million by 2029, representing a compound annual growth rate of 7.8%. Brazil's Point of Care Diagnostics Market is experiencing accelerated growth driven by healthcare modernization initiatives and increased accessibility demands across the nation's diverse geography.
Brazil Point of Care Diagnostics Market Trends and Insights
- Brazil's healthcare infrastructure modernization and rising demand for rapid diagnostic solutions are driving market expansion across urban and emerging regions.
- The country's focus on decentralized healthcare delivery and infectious disease management continues to fuel adoption of point-of-care testing platforms. In Brazil, the market benefits from increasing healthcare expenditure, growing prevalence of chronic and infectious diseases, and government initiatives to strengthen primary care networks.
- Brazil's expanding middle class and improved access to diagnostic technologies are accelerating market penetration in both public and private healthcare settings.
- By 2029, Brazil is expected to solidify its position as a key growth market within Latin America's point-of-care diagnostics sector..
Key Market Statistics
- CAGR (2024-2029) 7.8% CAGR
- Market Size, 2024 ~USD 158.8 Million
- Forecast, 2029 ~USD 231.4 Million
- Country Brazil
Brazil Point of Care Diagnostics Market Overview
Market Valuation :
Brazil's Point of Care Diagnostics Market is valued at USD 158.8 million in 2024, with strong growth trajectory positioning it as a key market in Latin America's healthcare diagnostics sector.
Healthcare Infrastructure Modernization :
Brazil is investing significantly in upgrading its healthcare infrastructure, creating increased demand for rapid diagnostic solutions in both public and private healthcare facilities across urban and emerging regions.
Decentralized Healthcare Expansion :
The country's strategic focus on decentralized healthcare delivery is driving adoption of point-of-care testing in remote and underserved areas, expanding market penetration beyond major metropolitan centers.
Robust Growth Projection :
With a CAGR of 7.8% through 2029, Brazil's market is expected to reach USD 231.4 million, outpacing many regional competitors and reflecting strong demand for accessible diagnostic technologies.
Brazil Point of Care Diagnostics Market Dynamics
- The market's 7.8% CAGR reflects growing adoption of rapid diagnostic solutions in both urban centers and emerging regions, supported by government healthcare reforms and private sector investments in diagnostic infrastructure. Looking ahead to 2029, Brazil's market expansion will be fueled by rising healthcare spending, technological advancement in portable diagnostics, and the country's commitment to decentralized healthcare delivery.
- Increasing prevalence of chronic diseases and infectious conditions, combined with improved healthcare awareness, will continue to drive demand for point-of-care testing solutions across hospitals, clinics, and community health centers throughout Brazil..
Related Ecosystem
In Vitro Diagnostics
- Polymerase Chain Reaction (PCR)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Dna Microarrays
- Assay Kits
- Microarrays
- ROCHE HOLDINGS AG
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Abbott Laboratories
- Biomerieux s.a.
Medical Devices
- Polymerase Chain Reaction (PCR)
- Magnetic Resonance Imaging (MRI)
- Disposable Autoinjectors
- Pulse Oximeters
- Blood Pressure Monitors
- Medtronic plc
- Stryker Corporation
- Abbott Laboratories
- Becton, Dickinson and Company
- JOHNSON & JOHNSON
Key Takeaways
- Brazil's Point of Care Diagnostics Market is valued at USD 158.8 million in 2024 and will reach USD 231.4 million by 2029 at a 7.8% CAGR.
- Brazil's healthcare modernization and decentralized care initiatives are accelerating adoption of rapid diagnostic solutions across public and private sectors.
- Rising prevalence of infectious and chronic diseases in Brazil is driving demand for point-of-care testing in primary care and remote settings.
- Brazil's expanding middle class and government healthcare investments position the country as a high-growth market within Latin America through 2029.
Point of Care Diagnostics Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | INFECTIOUS DISEASE TESTING PRODUCTS (Product) |
| Forecast Period | 2024–2029 |
| Growth Rate | CAGR of 8.5% from 2024 to 2029 |
| Largest Segment | BLOOD SAMPLES (Sample) |
| Market Size Base Year (Billions) | ~USD 15.05 (2024) |
| Revenue Forecast (Billions) | ~USD 22.63 (2029) |
| Segments Covered | Product, Type, Sample, End User, Mode Of Purchase, Technology |
Brazil Point of Care Diagnostics Market Report Segmentation
6 segment dimensions are covered across the global market.
By Product
- Cardiometabolic Monitoring Products
- Cholesterol Testing Products
- Coagulation Monitoring Products
- Drugs-Of-Abuse Testing Products
- Fecal Occult Testing Products
- Glucose Monitoring Products
- Hematology Testing Products
- Infectious Disease Testing Products
- Other Products
- Pregnancy & Fertility Testing Products
- Thyroid Stimulating Hormone Testing Products
- Tumor/Cancer Marker Testing Products
- Urinalysis Testing Products
By Type
- Act/Apit Testing Products
- Blood Gas/ Electrolyte Testing Products
- Cardiac Marker Testing Products
- Chlamydia Trachomatis Testing Products
- Clostridium Difficile Infection Testing Products
- Fertility Testing Products
- Glucose Monitoring Lancets & Lancing Devices
- Glucose Monitoring Meters
- Glucose Monitoring Strips
- Hba1C Testing Products
- Healthcare-Associated Infection Testing Products
- Hepatitis B Testing Products
- Hepatitis C Testing Products
- Hepatitis Testing Products
- Herpes Simplex Virus Testing Products
- Hiv Testing Products
- Human Papillomavirus Testing Products
- Inaat
- Influenza Testing Products
- Meters
- Neisseria Gonorrhea Testing Products
- Neisseria Gonorrhoea Testing Products
- Other Infectious Disease Testing Products
- Other Respiratory Infection Testing Products
- Pregnancy Testing Products
- Pt/Inr Testing Products
- Respiratory Infection Testing Products
- Rt-Pcr
- Sexually Transmitted Disease Testing Products
- Strips
- Syphilis Testing Products
- Tropical Disease Testing Products
- Tuberculosis
By Sample
- Blood Samples
- Nasal & Oropharyngeal Swabs
- Other Samples
- Urine Samples
By End User
- Ambulatory Care Facilities And Physician Offices
- Clinical Laboratories
- Home Care Settings And Self-Testing
- Hospitals, Critical Care Centers, And Urgent Care Centers
- Other End Users
By Mode Of Purchase
- Otc Testing Products
- Prescription-Based Testing Products
By Technology
- Biochemistry
- Immunoassays
- Molecular Diagnostics
Target Audience
- In Vitro Diagnostics Manufacturers : IVD companies seeking to expand their Brazil operations need detailed market insights on POC diagnostic adoption rates, healthcare facility distribution, and regulatory pathways specific to the Brazilian market.
- Healthcare Investment Firms : Private equity and venture capital investors evaluating opportunities in Brazil's healthcare sector require comprehensive market data, growth projections, and competitive analysis to support investment thesis development.
- Medical Device Distributors : Distributors and importers operating in Brazil need market-specific intelligence on demand patterns, regional variations, and healthcare facility types to optimize inventory and distribution strategies.
- Healthcare System Administrators : Hospital networks and public health administrators in Brazil require market insights to inform procurement decisions, technology adoption strategies, and budget allocation for diagnostic infrastructure.
- Market Research & Strategy Consultants : Consulting firms advising healthcare clients on Brazil expansion strategies need reliable, country-specific market data to develop competitive positioning recommendations and market entry plans.
Key Companies in the Brazil Point of Care Diagnostics Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| CEPHEID INC. | United States | Private Company | Infectious Disease POC (TB, HAI, STD, virology),Oncology and Genetics POC / near-patient MDx,Other POC (including emergency use, emerging pathogens such as Ebola), |
| UNILABS | Switzerland | Private Company | Glucose POC (primarily hospital and clinic-based),Infectious Disease POC (TB, HAI, STD),Pregnancy and Fertility-Linked POC, |
| EIKEN CHEMICAL CO., LTD. | Japan | Public Company | Glucose (POC),Infectious Disease POC (TB, HAI, STD and others),Pregnancy and other immunological POC tests, |
| ABBOTT | United States | Public Company | Glucose (POC and home monitoring within scope),Infectious Disease POC (including TB, HAI, STD, respiratory, HIV, others),Pregnancy and fertility POC, |
| SIEMENS HEALTHINEERS AG | Germany | Public Company | Glucose (Rx and OTC POC),Infectious Disease POC (TB, HAI, STD and others),Pregnancy and Fertility POC, |
| DANAHER | United States | Public Company | Glucose POC,Infectious Disease POC (incl. TB, HAI, STD),Pregnancy and Fertility POC, |
| QUIDELORTHO CORPORATION | United States | Public Company | POC Infectious Disease (incl. TB, HAI, STD, respiratory),POC Pregnancy and Fertility,POC Glucose and Metabolic, |
| BD | United States | Public Company | Glucose POC,Infectious Disease POC (TB, HAI, STD),Pregnancy and Other POC, |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Glucose POC,Infectious Disease POC (TB, HAI, STD and others),Pregnancy and Fertility POC, |
| BIOMéRIEUX | France | Public Company | Infectious Disease POC (TB, HAI, STD, respiratory via BIOFIRE/SPOTFIRE, ARGENE near-patient use),Pregnancy and other immunoassay POC (VIDAS and related markers in near-patient settings),Glucose and basic biochemistry POC, |
| BIOSYNEX SA | France | Public Company | Glucose POC,Infectious Disease POC (TB, HAI, STD and others),Pregnancy and Fertility POC, |
| EKF DIAGNOSTICS HOLDINGS PLC | United Kingdom | Public Company | Glucose and Lactate Analyzers (Biosen, Lactate Scout, related),HbA1c and Hemoglobin POC Analyzers (Quo-Lab, Quo-Test, DiaSpect, Hemo Control, Hemo Vet),Pregnancy and Fertility (QuPID, True20, Creamatocrit Plus), |
| TRINITY BIOTECH | Ireland | Public Company | Glucose / Diabetes (incl. HbA1c-linked POC),Infectious Disease POC (TB, HAI, STD, viral),Pregnancy and Fertility POC, |
| BODITECH MED INC. | South Korea | Public Company | Glucose (POC),Infectious Disease (TB, HAI, STD, COVID-19 and others),Pregnancy and Fertility, |
CEPHEID INC.
CEPHEID INC. is a United States-based private company founded in 1996 with 1,700 employees specializing in molecular diagnostics.
UNILABS
UNILABS is a Swiss private company established in 1987 that operates clinical laboratory services with 1,897 employees.
EIKEN CHEMICAL CO., LTD.
EIKEN CHEMICAL CO., LTD. is a Japanese public company founded in 1939 with 696 employees engaged in chemical and diagnostic manufacturing.
ABBOTT
ABBOTT is a United States-based public company founded in 1888 with 115,000 employees operating in healthcare and diagnostics.
SIEMENS HEALTHINEERS AG
SIEMENS HEALTHINEERS AG is a German public company founded in 1896 with 72,369 employees providing medical technology and diagnostics solutions.
DANAHER
DANAHER is a United States-based public company founded in 1969 with 59,000 employees operating in diagnostics and life sciences.
QUIDELORTHO CORPORATION
QUIDELORTHO CORPORATION is a United States public company founded in 1979 with 6,500 employees specializing in diagnostic testing.
BD
BD is a United States-based public company founded in 1897 with 72,000 employees in medical technology and diagnostics.
THERMO FISHER SCIENTIFIC INC.
THERMO FISHER SCIENTIFIC INC. is a United States public company founded in 1956 with 125,000 employees providing life sciences and diagnostics solutions.
BIOMéRIEUX
BIOMéRIEUX is a French public company founded in 1963 with 14,894 employees specializing in in vitro diagnostics.
BIOSYNEX SA
BIOSYNEX SA is a French public company founded in 2005 with 397 employees in the diagnostic testing sector.
EKF DIAGNOSTICS HOLDINGS PLC
EKF DIAGNOSTICS HOLDINGS PLC is a United Kingdom public company founded in 1990 with 301 employees in clinical diagnostics.
TRINITY BIOTECH
TRINITY BIOTECH is an Irish public company founded in 1992 with 287 employees engaged in diagnostic product development.
BODITECH MED INC.
BODITECH MED INC. is a South Korean public company founded in 1998 with 541 employees in diagnostic device manufacturing.
Reasons to Buy this Report
- Market-Specific Growth Data : Access detailed Brazil-specific market sizing, CAGR analysis, and five-year forecasts to accurately assess investment opportunities and competitive positioning in this high-growth Latin American market.
- Healthcare Infrastructure Insights : Understand Brazil's modernization initiatives and decentralized healthcare expansion strategies that are reshaping diagnostic adoption patterns and creating new market entry opportunities for POC solution providers.
- Regional Expansion Strategy : Identify growth opportunities across urban centers and emerging regions with detailed analysis of market penetration potential, helping companies develop targeted expansion strategies for Brazil's diverse healthcare landscape.
- Competitive Landscape Analysis : Gain insights into Brazil's competitive dynamics, key market players, and differentiation strategies specific to the country's regulatory environment and healthcare procurement processes.
- Investment Decision Support : Make informed investment and partnership decisions with comprehensive Brazil market data, including demand drivers, barriers to entry, and long-term growth sustainability through 2029.
Frequently asked questions
What is the current size of Brazil's Point of Care Diagnostics Market?
Brazil's Point of Care Diagnostics Market is valued at USD 158.8 million in 2024.
What is the projected market size for Brazil by 2029?
Brazil's Point of Care Diagnostics Market is projected to reach USD 231.4 million by 2029.
What is the CAGR for Brazil's Point of Care Diagnostics Market?
Brazil's Point of Care Diagnostics Market is expected to grow at a compound annual growth rate (CAGR) of 7.8% from 2024 to 2029.
What factors are driving growth in Brazil's Point of Care Diagnostics Market?
Key growth drivers in Brazil include healthcare infrastructure modernization, government initiatives for decentralized care, rising disease prevalence, and increased healthcare expenditure.
How does Brazil's market compare to the global Point of Care Diagnostics Market?
Brazil's 7.8% CAGR is slightly below the global average of 8.5%, reflecting regional market maturity and localized growth dynamics within Latin America.
RESEARCH METHODOLOGY
The study involved major activities to estimate the current market size of the Point of Care diagnostics market. Exhaustive secondary research was conducted to gather information on the market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the POC diagnostics market.
Secondary Research
This research study involved the extensive use of secondary sources, directories, databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva, white papers, and Companies House documents. Secondary research was undertaken to identify and collect information for this extensive, technical, market-oriented, and commercial study of the POC diagnostics market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various supply- and demand-side sources were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side included industry experts such as CEOs, VPs/Managing Directors, Marketing Heads/Directors, Sales Directors, Marketing/Sales Managers, Regional/Area Sales Managers, Export/Import Heads/Managers, and Other Market-Related Personnel from various companies and organizations operating in the POC diagnostics market. Primary sources from the demand side included Law Enforcement Agencies, Vice Presidents, C-level Executives, Department Heads, Enterprises, Individuals, Supply Management Teams of Hospitals, Clinic Personnel, and Laboratory Technicians.
Note 1: C-level primaries include CEOs, COOs, CTOs, and VPs.
Note 2: Other primary roles include sales, marketing, and product management.
Note 3: Companies are classified into tiers based on their total revenue. As of 2025: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the POC diagnostics market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Data Triangulation
The entire market was split into two segments when the market size was determined. Data triangulation and market breakdown were used as needed to complete the market engineering process and derive precise statistics for all segments.
Approach for deriving the market size and estimating market growth:
Using secondary data from paid and unpaid sources, the market rankings for the major players were determined through a thorough analysis of their POC diagnostic sales. Due to data restrictions, the revenue share in certain cases was determined after a thorough analysis of the product portfolio of big corporations and their individual sales performance. This information was verified at each stage by in-depth interviews with professionals in the field.
Market Definition
Point-of-care (POC) diagnostics refers to diagnostic testing performed at or near the patient's location, delivering rapid and accurate results to support immediate clinical decision-making. The market includes products such as blood glucose monitoring systems, infectious disease tests, cardiac biomarker assays, coagulation testing, blood gas and electrolyte analyzers, molecular diagnostics, pregnancy and fertility tests, urinalysis, and other rapid diagnostic solutions, serving hospitals, clinical laboratories, physician offices, ambulatory care facilities, retail clinics, pharmacies, and home healthcare settings.
Key Stakeholders
- Diagnostic device manufacturers
- Reagent and consumable suppliers
- Hospitals and clinical laboratories
- Physician offices and ambulatory care centers
- Pharmacies and home healthcare providers
- Medical device distributors
- Regulatory authorities
- Government and public health agencies
- Research organizations
- Healthcare IT providers
Report Objectives
- To describe, analyze, and forecast the POC diagnostics market, by product, sample, mode of purchase, technology, end user, and region
- To describe and forecast the POC diagnostics market for key regions, namely, North America, Europe, the Asia Pacific, Latin America and Middle East, and Africa
- To provide detailed information regarding drivers, restraints, opportunities, and challenges influencing the growth of the POC diagnostics market
- To strategically analyze the ecosystem, regulations, patenting trend, value chain, Porter’s five forces, and prices pertaining to the market under study
- To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for market players
- To profile key players and comprehensively analyze their market shares and core competencies2 in the POC diagnostics market
- To analyze competitive developments such as collaborations, acquisitions, product launches, expansions, and R&D activities in the POC diagnostics market
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to 5)
Product Analysis
- Product matrix, which gives a detailed comparison of the product portfolios of each company
Geographic Analysis
- Further breakdown of the Rest of Asia Pacific POC diagnostics market into Vietnam, New Zealand, and other markets.
- Further breakdown of the Rest of Latin America POC diagnostics market into Colombia, Chile, Ecuador, and others.
- Further breakdown of the Rest of Europe POC diagnostics market into Belgium, Russia, the Netherlands, Switzerland, and others.
Get the Full Point of Care Diagnostics Market Report
Full forecast, segment splits, and company analysis for all Point of Care Diagnostics Market.
- Canada Point of Care Diagnostics Market
- US Point of Care Diagnostics Market
- Germany Point of Care Diagnostics Market
- France Point of Care Diagnostics Market
- UK Point of Care Diagnostics Market
- Italy Point of Care Diagnostics Market
- Spain Point of Care Diagnostics Market
- China Point of Care Diagnostics Market
- Japan Point of Care Diagnostics Market
- India Point of Care Diagnostics Market
- Australia Point of Care Diagnostics Market
- South Korea Point of Care Diagnostics Market
- Mexico Point of Care Diagnostics Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report